```html

Xanthine Oxidation Deficiency (XOD)

What is Xanthine oxidation deficiency?

Xanthine oxidation deficiency (XOD) is a rare metabolic disorder caused by a deficiency of the enzyme xanthine oxidase (also known as xanthine dehydrogenase). This enzyme plays a crucial role in the purine‑degradation pathway, converting hypoxanthine to xanthine and xanthine to uric acid. When the enzyme is deficient, purines accumulate as hypoxanthine and xanthine, while uric acid production falls dramatically. The condition may be inherited (autosomal recessive) or acquired due to drug exposure, liver disease, or other metabolic disturbances.

Because uric acid is a major antioxidant in plasma, individuals with XOD often have low serum uric acid levels (hypouricemia) and may develop kidney stones composed of xanthine, a relatively insoluble compound. The disorder is sometimes called “xanthinuria” when stone formation dominates the clinical picture.

Common Causes

Below are the most frequently identified causes of xanthine oxidation deficiency. In many patients the cause remains unknown (idiopathic).

• Genetic Xanthinuria Type I – Autosomal recessive mutation in the XDH gene leading to isolated xanthine oxidase deficiency.
• Genetic Xanthinuria Type II – Mutation in the MOCOS gene that impairs the molybdenum cofactor required for xanthine oxidase activity.
• Acquired drug‑induced inhibition – High‑dose allopurinol, febuxostat, or other purine‑analogue drugs can transiently suppress xanthine oxidase.
• Severe liver disease – Cirrhosis or acute hepatic failure can reduce enzyme synthesis.
• Molybdenum cofactor deficiency – Rare hereditary disorder that disables several molybdenum‑dependent enzymes, including xanthine oxidase.
• Renal tubular disorders – Certain proximal tubulopathies interfere with purine handling, augmenting xanthine accumulation.
• Heavy‑metal poisoning – High levels of lead or mercury may inhibit the enzyme activity.
• Severe malnutrition or protein‑energy wasting – Diminished availability of cofactors for enzyme synthesis.
• Chronic inflammatory states – Prolonged cytokine exposure can down‑regulate xanthine oxidase expression.
• Rare mitochondrial disorders – Some mitochondrial DNA mutations affect purine metabolism indirectly.

Associated Symptoms

Because the biochemical defect is usually silent, many patients are diagnosed incidentally when a blood test shows low uric acid or when a kidney stone is discovered. When symptoms do appear, they usually involve the urinary tract or metabolic disturbances.

• Recurrent renal (xanthine) stones – flank pain, hematuria, urinary obstruction.
• Chronic lower‑back or abdominal pain from stone passage.
• Frequent urinary tract infections (UTIs) secondary to obstruction.
• Low or absent serum uric acid (hypouricemia) on routine labs.
• Fatigue or muscle weakness (non‑specific, often related to underlying liver or renal disease).
• Growth retardation in children with severe, untreated XOD.
• Occasional gout‑like arthralgias are rare because uric acid is low, but joint pain can result from crystal deposition of other purines.
• Neurologic signs (rare) – seizures or developmental delay in those with combined molybdenum cofactor deficiency.

When to See a Doctor

Although XOD is uncommon, certain red‑flag signs should prompt timely medical evaluation:

• Sudden, severe flank pain that radiates to the groin (possible stone).
• Visible blood in the urine (hematuria) lasting more than 24 hours.
• Repeated urinary tract infections or unexplained fever with urinary symptoms.
• Laboratory results showing persistently low uric acid (< 2 mg/dL) without an obvious cause.
• Kidney‑function decline (rising creatinine) without another clear etiology.
• Unexplained growth delay or developmental concerns in a child.

Diagnosis

Diagnosing XOD requires a combination of biochemical testing, imaging, and sometimes genetic analysis.

1. Laboratory Studies

• Serum uric acid – Typically < 2 mg/dL (low).
• Urine purine profile – Elevated xanthine and hypoxanthine with low uric acid; a 24‑hour collection provides quantitative data.
• Enzyme activity assay – Measurement of xanthine oxidase activity in blood leukocytes or liver biopsy (rarely needed).
• Kidney function panel – Creatinine, BUN, electrolytes.
• Genetic testing – Sequencing of XDH and MOCOS genes confirms hereditary forms; commercially available panels can detect both types.
• Heavy‑metal screen – Blood lead or mercury levels if exposure is suspected.

2. Imaging

• Non‑contrast CT of the abdomen/pelvis – Gold standard for detecting radiopaque xanthine stones.
• Ultrasound – Useful for bedside evaluation of hydronephrosis or stones in pregnant patients.
• Kidney‑ureter‑bladder (KUB) X‑ray – May miss stones because xanthine is less radiopaque than calcium.

3. Additional Tests

• Metabolic work‑up for molybdenum cofactor deficiency (serum sulfite, sulfamate).
• Liver function tests if hepatic disease is suspected.

Treatment Options

Therapy aims to prevent stone formation, manage existing stones, and correct any underlying metabolic abnormalities.

Medical Management

• Hydration – Drink at least 2.5–3 L of fluid per day (unless contraindicated) to keep urine volume >2 L/day and dilute xanthine concentrations.
• Alkalinization of urine – Sodium bicarbonate or potassium citrate to raise urine pH to 6.5–7.0, which increases xanthine solubility.
• Dietary purine restriction – Limit high‑purine foods (red meat, organ meats, sardines, anchovies, legumes, yeast extracts). Emphasize low‑purine fruits and vegetables.
• Allopurinol cessation – If a drug is causing secondary inhibition, discontinue under physician supervision.
• Supplemental molybdenum (rare) – In documented molybdenum cofactor deficiency, high‑dose oral molybdenum may improve enzyme activity, but must be monitored closely.
• Uric acid–raising agents – Occasionally, low‑dose uric acid precursors (e.g., inosine) are used to increase urinary uric acid, which can act as a crystallization inhibitor, but evidence is limited.

Procedural/Surgical Management

• Extracorporeal shock wave lithotripsy (ESWL) – First‑line for small (< 2 cm) stones.
• Ureteroscopic stone removal – Preferred for larger or impacted stones.
• Percutaneous nephrolithotomy (PCNL) – Used for massive stone burden.
• Stent placement – Temporarily relieves obstruction while definitive treatment is planned.

Home Care & Lifestyle

• Maintain a urine output >2 L/day; monitor fluid intake.
• Avoid dehydration‑promoting drinks (excessive caffeine, alcohol).
• Regularly strain urine (using a fine mesh) to catch any passed stones for analysis.
• Schedule periodic urine pH checks with home test strips.

Prevention Tips

While genetic forms cannot be prevented, many steps can lower the risk of stone formation and complications.

• Stay well‑hydrated – Aim for at least 8–10 glasses of water daily; more in hot climates.
• Alkaline diet – Incorporate fruits (e.g., bananas, apples) and vegetables that raise urine pH.
• Moderate protein intake – Excess animal protein increases purine load.
• Limit fructose‑sweetened beverages – Fructose can increase purine synthesis.
• Regular follow‑up labs – Annual serum uric acid and 24‑hour urine purine testing for known carriers.
• Genetic counseling – Families with known XOD should receive counseling before planning pregnancies.
• Avoid nephrotoxic medications – NSAIDs, certain antibiotics, and contrast agents can precipitate kidney injury in the setting of obstruction.

Emergency Warning Signs

Key Take‑aways

• Xanthine oxidation deficiency is a rare disorder of purine metabolism that leads to low uric acid and xanthine stone formation.
• Both genetic (Type I, Type II) and acquired (drug, liver disease, heavy metals) causes exist.
• Symptoms often revolve around kidney‑related pain, hematuria, and recurrent urinary stones.
• Diagnosis requires serum/urine testing, imaging, and sometimes genetic analysis.
• Management emphasizes high fluid intake, urine alkalinization, purine‑restricted diet, and appropriate stone‑removal procedures.
• Prompt attention to emergency warning signs can prevent kidney damage and life‑threatening infection.

For personalized advice, always discuss your symptoms and test results with a qualified healthcare provider. The information above is intended for educational purposes and should not replace professional medical evaluation.

---

Sources: Mayo Clinic, National Institutes of Health (NIH) – Genetic and Rare Diseases Information Center, American Urological Association Guidelines, Cleveland Clinic, World Health Organization (WHO), and peer‑reviewed articles in Kidney International and Journal of Inherited Metabolic Disease (2022‑2024).

```